Monod
monod.bio
Actively hiring
AI for Science
Molecular Diagnostics
Biosensors
Synthetic Biology
As featured in
View 1 job
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Total raised
$30.2M
3 rounds on record
Latest round
$24.2M
Seed · Jun 2022 · 4 yr ago
Team
51-200
employees, estimated range
Hiring now
1
+1 posted in 30 days
Grants
$290k
1 grant · CORDIS
The money's age
Long since its last round
52 months since the last round · and hiring
Momentum
28/100
hiring for its size, in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 26
Board appointment Monod Bio Announces Appointment of Robert J. Bujarski to Board of Directors · monod.bio
Dec 3, 2025
Partnership Monod Bio and Gator Bio Partner to Develop Next-Generation Biosensors for Advanced Life Science Research · monod.bio
Oct 1, 2025
Board appointment Monod Bio Announces Appointment of Timothy I. Still as Executive Chairman · monod.bio
Sep 30, 2024
Launched Monod Bio Launches CRP Biosensor on New NovoLISA Platform · monod.bio
Jan 1, 2024
Won a grant $290k · CORDIS
Jun 10, 2022
Raised a round Seed $24.2M · SEC Form D
Nov 29, 2021
Raised a round Convertible Note $6M · SEC Form D
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2024 | $290k | — | CORDIS |
| Seed | Jun 2022 | $24.2M | — | SEC Form D |
| Convertible Note | Nov 2021 | $6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Monod Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Daniel Silva ManzanoExecutive Officer, DirectorSEC Form D
David ShoultzExecutive Officer, DirectorSEC Form D
Alfredo RubioExecutive OfficerSEC Form D
Alfredo Quijano RubioExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
BioGeometry is a digital biology pioneer that specializes in applying generative AI to protein design.
Headquartered in Tel Aviv, Israel, Scala Biodesign is a biotechnology company developing computational protein design and enzyme…
Florey is a Boston-based company that uses synthetic biology to create and improve beneficial micro-organisms for human health.
Accipiter Biosciences designs de novo, multifunctional protein biologics to treat complex diseases through advanced computational protein…
Asimov builds tools to program living cells. We're integrating mammalian synthetic biology with computer-aided design to advance…
Discover Omni 1000, the revolutionary proteomics platform offering 1000 high-fidelity proteins for cost-effective and rapid analysis in any…
News
Global Health at Monod
Global Health at Monod BioEngineering the future of clinical diagnostics and life sciences tools to solve the world's most pressing health challenges. Spotlight on our global health initiatives Tuberculosis Tuberculosis is the world's deadliest infectious
Read more
Report
LuxSit Pro
LuxSit Pro LuxSit Pro The LuxSit Pro Luciferase Assay System generates high-intensity glow-type luminescence multiple times brighter than the commonly used Firefly & Renilla luciferase systems.The Monod Bio LuxSit Pro products are offered as kits that ena
Read more
Report
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
SEATTLE and RICHMOND, British Columbia - August 26th, 2026 - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive lice
Read more
Report
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio
Read more
Report
EQS-News: Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
LuxLink for NovoLISA
LuxLink: Rapid Conjugation System for Custom NovoLISA Monod Bio's NovoLISA is a rapid, no-wash (homogeneous) immunoassay powered by state-of-the-art Split LuxSit (LuxSit sPro) Luciferase technology. The system utilizes two small fragments- βit (1.5 kDa) a
Read more
Report
Monod Bio Announces Appointment of Robert J. Bujarski to Board of Directors
- Seasoned industry leader with over 20 years of experience joins as Monod Bio advances strategic growth and operational scaling SEATTLE, WA - February 26, 2026 - Monod Bio, a leader in computational protein design, today announced the appointment of Robe
Read more
Report
Gator Bio Launches HIS XT Probes with AI-Designed NovoBody Technology, Delivering Superior Performance for His-Tagged Protein Analysis
Industry-first probes featuring computationally designed binding proteins provide unprecedented affinity, baseline stability, and data quality for antibody characterization and biologics research PALO ALTO, CA & Seattle, WA, February 18, 2026 - Gator Bio,
Read more
Report
Monod Bio and Gator Bio Partner to Develop Next-Generation Biosensors for Advanced Life Science Research
Gator will integrate one of Monod's AI-designed NovoBody binding proteins into its industry-leading biolayer interferometry platform NovoBody binding proteins deliver superior performance, stability, and engineerability compared to traditional monoclonal
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Monod over the last 12 months, by layer, with the share of postings for each.
Technologies in use
4
Postings analysed
1
Stack modernity
53/100
Developer tools
Benchling
Practices & domains
Chromatography
Flow Cytometry
PCR
Sign in to see how your skills match this stack
Sign In
People
Daniel Silva Manzano
Executive Officer, Director
David Shoultz
Executive Officer, Director
Alfredo Rubio
Executive Officer
Alfredo Quijano Rubio
Executive Officer
Dave Johnson
Director
Berta Cimler
Director
Karan Takhar
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
48/100
Stable
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~5 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Seattle
Seattle
United States
HQ
Contact Us
1 open roles 1 posted in 90 days 100% engineering 50-200 est. staff
hires for Science & Research
700 Dexter Ave N, Suite 700, Seattle, Washington 98109, US
Jobs
≈ $95k – $188k per year (Estimated) · In office · 2+ years exp · Bachelor's Degree · Seattle
PCR
Flow Cytometry
Chromatography
Benchling
Apply